ID   MDA-MB-468 shWDR12-4
AC   CVCL_YJ27
DR   cancercelllines; CVCL_YJ27
DR   Wikidata; Q95987445
RX   CelloPub=CLPUB00550;
CC   Group: Triple negative breast cancer (TNBC) cell line.
CC   Population: African American.
CC   Doubling time: 24-31 hours (CelloPub=CLPUB00550).
CC   Knockout cell: Method=shRNA knockdown; HGNC; 14098; WDR12.
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.253+1G>T; ClinVar=VCV000189475; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Simple; c.265_2787del2523; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line).
CC   Miscellaneous: Corrections of STR profile from thesis manuscript (CelloPub=CLPUB00550) from personal communication of Al-Awar R.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): CelloPub=CLPUB00550; Direct_author_submission
ST   Amelogenin: X
ST   CSF1PO: 12,13
ST   D13S317: 12
ST   D16S539: 9
ST   D21S11: 27,28
ST   D5S818: 12
ST   D7S820: 8
ST   TH01: 7
ST   TPOX: 8,9
ST   vWA: 18
DI   NCIt; C5214; Breast adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0419 ! MDA-MB-468
SX   Female
AG   51Y
CA   Cancer cell line
DT   Created: 19-12-19; Last updated: 05-10-23; Version: 10
//
RX   CelloPub=CLPUB00550;
RA   Benhamron S.;
RT   "Validating WDR12 as a potential drug target in triple negative breast
RT   cancer.";
RL   Thesis MSc (2019), University of Toronto, Canada.
//